Priscilla Guglielmo, Michela Olivieri, Luca Filippi, Katia Marzo, Jelena Jandric, Marcello Rodari, Manuela Marenco, Laura Evangelista
{"title":"Liver metastases in breast cancer: [<sup>18</sup>F]FDG and radioembolization as strategies for diagnosis and treatment.","authors":"Priscilla Guglielmo, Michela Olivieri, Luca Filippi, Katia Marzo, Jelena Jandric, Marcello Rodari, Manuela Marenco, Laura Evangelista","doi":"10.1080/17434440.2025.2526682","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This review aims to analyze the role of [<sup>18</sup>F]FDG PET/CT and transarterial radioembolization (TARE) in managing liver metastases (LM) in breast cancer (BC), from metabolic characterization to treatment, to assess their impact on patient outcomes.</p><p><strong>Areas covered: </strong>A systematic search in PubMed and Embase (up to October 2024) identified studies on [<sup>18</sup>F]FDG PET imaging for LM in BC. Filters excluded reviews, case reports, and abstracts. Twenty-seven papers were selected, 19 were relative to the accuracy of [<sup>18</sup>F]FDG PET/CT and 8 to TARE. [<sup>18</sup>F]FDG PET/CT detected distant metastases in 10-100% of cases and LM in 0.3-38%. In most studies, PET/CT outperformed ceCT in detecting LM, though one study reported higher detection with ceCT (30.3% vs. 21.1%). The overall response rate to TARE was superior to 60%, while the overall survival ranged from 6.1 to 35.4 months, with minor severe adverse events.</p><p><strong>Expert opinion: </strong>[<sup>18</sup>F]FDG PET/CT has a high accuracy in LM detection, and TARE has a high therapeutic potential in metastatic BC. Indeed, the optimization of imaging and personalized treatment strategies may enhance patient outcomes, also by considering the future perspectives.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"999-1008"},"PeriodicalIF":2.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of medical devices","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17434440.2025.2526682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This review aims to analyze the role of [18F]FDG PET/CT and transarterial radioembolization (TARE) in managing liver metastases (LM) in breast cancer (BC), from metabolic characterization to treatment, to assess their impact on patient outcomes.
Areas covered: A systematic search in PubMed and Embase (up to October 2024) identified studies on [18F]FDG PET imaging for LM in BC. Filters excluded reviews, case reports, and abstracts. Twenty-seven papers were selected, 19 were relative to the accuracy of [18F]FDG PET/CT and 8 to TARE. [18F]FDG PET/CT detected distant metastases in 10-100% of cases and LM in 0.3-38%. In most studies, PET/CT outperformed ceCT in detecting LM, though one study reported higher detection with ceCT (30.3% vs. 21.1%). The overall response rate to TARE was superior to 60%, while the overall survival ranged from 6.1 to 35.4 months, with minor severe adverse events.
Expert opinion: [18F]FDG PET/CT has a high accuracy in LM detection, and TARE has a high therapeutic potential in metastatic BC. Indeed, the optimization of imaging and personalized treatment strategies may enhance patient outcomes, also by considering the future perspectives.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
